Since the discovery of post-translational modification (PTM) by the small ubiquitin-related modifiers (SUMOs), a multitude of proteins have been described to be reversibly modified, resulting in the alteration of several cellular pathways. Interestingly, various pathogens gain access to this modification system, although the molecular mechanisms and functional consequences are barely understood. We show here that the adenoviral oncoprotein E1B-55K is a substrate of the SUMO conjugation system, which is directly linked to its C-terminal phosphorylation. This regulative connection is indispensable for modulation of the tumor suppressor p53/chromatin-remodeling factor Daxx by E1B-55K and, consequently, its oncogenic potential in primary mammalian cells. In virus infection, E1B-55K PTMs are necessary for localization to viral transcription/replication sites. Furthermore, we identify the E2 enzyme Ubc9 as an interaction partner of E1B-55K, providing a possible molecular explanation for SUMO-dependent modulation of cellular target proteins. In conclusion, these results for the first time provide evidence how E1B-55K PTMs are regulated and subsequently facilitate exploitation of the host cell SUMOylation machinery.
INTRODUCTION
Ubiquitin-like proteins compose one of the most prominent families of small modifiers. 1 One of its members, termed small ubiquitin-related modifier (SUMO), has been discovered in the 1990s and extensively characterized by a lot of different laboratories. Currently, modification by SUMO-1, SUMO-2 and SUMO-3 has been shown to regulate a diverse number of cellular processes, including protein degradation, chromatin structure, subnuclear localization, transcription factor activity, proteinprotein interaction, nuclear/cytoplasmic shuttling and the integrity of promyelocytic leukemia (PML)-nuclear bodies (PML-NBs). [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Although detailed data about the enzymatic machinery of SUMO conjugation are available (Figure 1a ), many questions remain to be answered about the regulation and corresponding downstream effects of SUMOylation. Moreover, the observation that multiple cellular pathways are extensively regulated by this post-translational modification (PTM), while only a low percentage of effector proteins are modified, represents one of the most puzzling questions, aptly termed as SUMO enigma. 6 The human Adenovirus type 5 early region 1B 55KDa (HAdV5 E1B-55K) is a multifunctional phosphoprotein, mediating several critical steps during the early and late phase of infection (reviewed in Berk 2007 13 and Berk 2005 14 ) . Initially, E1B-55K counteracts antiproliferative processes induced by the host cell, including activation of p53-dependent and independent apoptosis, induction of cell cycle arrest and stimulation of cellular DNA damage response (reviewed in Weitzman 2005 et al. 15 and White 2001 16 ). In the late phase, the adenoviral protein stimulates efficient cytoplasmic accumulation and translation of viral late mRNAs (reviewed in Dobner 2001 et al. 17 and Flint 2003 et al. 18 ).
Intriguingly, several pathogens take advantage of the cellular SUMOylation machinery, either by modulating essential components or being themselves targets of this PTM (reviewed in Boggio et al. 19 Wilson et al. 20 and Wimmer et al. 21 ). As described previously, E1B-55K undergoes two principle PTMs (Figure 1b) , namely SUMO-1 conjugation at a SUMO-1 conjugation motif (SCM; c-K 104 -x-E/D) [22] [23] [24] [25] [26] and phosphorylation by casein kinase 2 (CK2) within its C-terminal phosphorylation region (CPR). [27] [28] [29] Interestingly, mutational inactivation of either the E1B-55K SCM or CPR leads to remarkably similar alterations in the molecular functions of the viral protein. Both the SUMOylation-deficient mutant E1B-55K-SCM 30 and the phosphorylation-deficient mutant E1B-55K-S490/1/T495A 27, 28 (Figure 1c ), alternatively termed E1B-55K-3XPA, 31 fail to efficiently repress p53-mediated transactivation, nucleo-cytoplasmic relocalization of p53 and thus cellular transformation of primary mammalian cells. Although phosphorylation of substrates has been shown consistently to be a prerequisite for efficient SUMO modification, [32] [33] [34] a comparable mechanism linking both PTMs of E1B-55K has not been described yet. Moreover, the viral protein harbors a leucine-rich nuclear export sequence (NES) of the HIV-1 rev type (Figure 1b) . 22, 25, 26 Interestingly, functional inactivation of the E1B-55K-NES was shown to induce enhanced modification by SUMO-1, modulation of p53 activity and augmented transformation of primary mammalian cells. 22, 23, 35, 36 Further results link E1B-55K SUMOylation to interact/modulate certain isoforms of the tumor suppressor protein PML 37 and to the degradation of the chromatin-remodeling factor Daxx. 38 In summary, these results suggest that SUMO modification directly impacts on several important functions of the adenoviral protein, although the respective regulatory mechanisms remain unknown. As HAdV5 E1B-55K represents a well-established model system, the present study aims to analyze closer the nature/effects of SUMO modification of E1B-55K and functional downstream consequences such as viral-mediated cell transformation. RESULTS E1B-55K is modified by all SUMO paralogues, enabling SUMO-chain formation Currently, three different SUMO paralogues have been identified that are conjugated to the respective target proteins via the c-K-x-E/D motif ( Figure 1a) . Previous results highlighted the importance of SUMOylation for E1B-55K function; however, these functions have so far been exclusively linked to SUMO-1 modification. 22, 23, [35] [36] [37] [38] As published data suggest overlapping, but also considerably different consequences of SUMO-1, SUMO-2 or SUMO-3 attachment, 39, 40 we decided to investigate the potential of E1B-55K to be modified by SUMO paralogues other than SUMO-1. As all paralogues can be conjugated to the SCM in vitro, we performed our experiments in living cells to evaluate whether SUMO-2/3 attachment occurs in vivo.
To gain initial evidence whether E1B-55K is associated with different SUMO paralogues, we analyzed the subcellular association of E1B-55K with either endogenous SUMO-1 or SUMO-2/3 by confocal microscopy. As the viral protein actively shuttles between the nucleus and the cytoplasm, 25, 26, 41 localization was analyzed either with ( Figures 2C and D) or without (Figures 2A and B) inhibition of E1B-55K nuclear export. Interestingly, E1B-55K-wt/ E1B-55K-NES showed an association and accumulation in the nucleus with both endogenous SUMO-1 ( Simultaneously performed immunoprecipitation experiments with exogenously overexpressed SUMO-1, -2 or -3 additionally suggest covalent attachment of alternative SUMO paralogues to the adenoviral protein at K104R (Supplementary Figure 1A) . Moreover, multiple E1B-55K cross-reactive bands are apparent in the immunoblots, which may be due to mono-, as well as poly-SUMOylation of E1B-55K by SUMO-2 and SUMO-3 (Supplementary Figure 1B) . This possibility is quite conceivable as both modifiers have an internal SCM, enabling multiple conjugation and formation of SUMO chains similar to classical ubiquitination. Taken together, the results indicate that under the experimental conditions tested, E1B-55K might be modified by all three SUMO paralogues, possibly including polySUMOylation with SUMO-2 and SUMO-3.
E1B-55K phosphorylation effects subsequent SUMO modification As phosphorylation of substrates has been shown repeatedly to be a prerequisite for efficient SUMO modification, [32] [33] [34] we wanted to evaluate a putative connection of both E1B-55K PTMs. Therefore, we analyzed differences in SUMO attachment to E1B-55K species, including E1B-55K-3XPA, and E1B-55K-3XPD, another mutant that constitutively mimicks phosphorylation in the CPR by replacement of serine/threonine residues by aspartic acids (Figure 1c) .
Consistent with the data shown before ( Supplementary  Figure 1) , E1B-55K-NES exhibited the highest levels of SUMO modification ( Figure 3A, lane 4) , whereas E1B-55K-SCM was not SUMOylated ( Figure 3A , lane 3). Intriguingly, both E1B-55K proteins mutated in the CPR (3XPA, 3XPD) showed alterations in SUMO attachment ( Figure 3A , lanes 5 and 6). Upon cotransfection of any one of the three SUMO paralogues, E1B-55K-3XPD was comparably SUMOylated than E1B-55K-wt ( Figure 3A , lanes 2 and 6), whereas PTM was barely detected on E1B-55K-3XPA ( Figure 3A , lane 5). Moreover, visualization of HA-tagged SUMO molecules after immunoprecipitation of E1B-55K revealed mono-and poly-SUMO chains attached to the viral protein in a phosphorylationdependent manner ( Figure 3B ), as evident from multiple HA-reactive bands with E1B-55K-wt/-NES/-3XPD ( Figure 3B , lanes 2, 4 and 6) and no detectable modification for E1B-55K-SCM/-3XPA ( Figure 3B, lanes 3 and 5) . Interestingly, a comparable band pattern of endogenous SUMO-2/3 can be visualized after precipitation with E1B-55K-specific antibodies (Abs) ( Figure 3D ), again suggesting that the adenoviral protein might get multiply modified by SUMO-2/3 in vivo.
Finally, to prove a direct correlation between both PTMs, we analyzed SUMO modification of E1B-55K either after application of the kinase inhibitor DMAT, which partly inhibits CK2-mediated C-terminal phosphorylation of E1B-55K ( Figures 3E-G) , 29 or with selectively combined mutations within the E1B-55K coding sequence ( Figure 3H ). As shown previously, 29 application of the CK2 inhibitor DMAT leads to a reduction of E1B-55K phosphorylation (Figure 3Fb ) relative to the untreated controls (Figure 3Fa ), which correlates with the degree of E1B-55K SUMO modification (Figures 3Eb/Ea). However, as the inhibitory effects of DMAT are limited and not all C-terminal residues of E1B-55K might be exclusively targeted by CK2, 29 some degree of phosphorylation and SUMO modification is evident in the respective experiments ( Figures 3E and F) . Moreover, selectively combined mutations within the E1B-55K protein show that inactivation of the CPR completely abolished SUMOylation of E1B-55K-NES ( Figure 3H, lanes 4 and 7) , whereas the latter has repeatedly been shown to exhibit strongest PTM by SUMO (Supplementary Figure 1, Figure 3 ). Taken together, the results strongly indicated a cross-talk between C-terminal phosphorylation and SUMOylation of E1B-55K. These data for the first time link previously described, but thus far unrelated observations concerning different E1B-55K functions. 22, 23, 27, 28, 31 E1B-55K oncogenic properties are dependent on the cross-talk of both PTMs The pro-tumorigenic functions of E1B-55K had primarily been linked to the silencing of p53 tumor suppressor functions. It has been generally believed that E1B-55K induces p53 PTM and transcriptional repression, which in turn leads to functional inactivation of the cellular tumor suppressor. 35, 36, [42] [43] [44] [45] [46] Recently published data indicated that E1B-55K itself is a functional E3 SUMO-ligase, which in turn induces p53 SUMOylation and facilitates repression of p53 by spatial restriction to PML-nuclear bodies; 36 however, further data suggested additional p53-independent mechanisms of E1B-55K induced cellular transformation. 37, 38, 47, 48 As PTMs have been shown to be essential for E1B-55K oncogenic potential, 22, 23, 28 we decided to analyze whether the linkage of E1B-55K SUMOylation and phosphorylation might provide a unifying framework concerning the modulation of cellular proteins. To determine the p53-repression potential of the different E1B-55K mutants, we performed reporter gene assays using a luciferase reporter with an artificial ( Figure 4A ) or a cellular p53-dependent promoter ( Figure 4B ). As anticipated, E1B-55K-wt induced a dose-dependent reduction in reporter activity in both the experiments (Figures 4A and B, columns 3-5), whereas inactivation of the E1B-55K SCM or CPR significantly impaired p53-repression (Figures 4A and B, columns 6 and 8). Interestingly, E1B-55K-3XPD (Figures 4A and B, column 9) activity was comparable to that of E1B-55K-NES ( Figures 4A and B, column 7) , indicating that interlinking of phosphorylation and SUMO modifications directly impacts on repression of p53-dependent transcription.
Moreover, results by Penella et al. 35 and Mü ller and Dobner 36 showed that the viral E1B-55K protein induces SUMOylation of p53-dependent on the E1B-55K SUMOylation status, which in turn augments p53 inactivation by spatial restriction to PML-nuclear bodies. To determine further, the functional correlation of both E1B-55K PTMs, we analyzed the modulation of p53 by the viral proteins ( Figure 4C ). Coprecipitation of the viral protein by p53 clearly showed that all adenoviral mutants were capable of binding the tumor suppressor, indicating that PTM of E1B-55K is dispensible for this interaction ( Figure 4Ca , lanes 3-7). Consistent with previous findings (Figure 2 ; Figure 3 ), a SUMO-modified form of E1B-55K-wt and mutants (NES, 3XPD) was evident ( Figure 4Ca , lanes 3, 5 and 7), whereas E1B-55K-SCM or E1B-55K-3XPA showed no slower-migrating forms ( Figure 4Ca , lanes 4 and 6). Intriguingly, mutation of the E1B-55K CPR, either abrogating (E1B-55K-3XPA) or constitutively mimicking phosphorylation (E1B-55K-3XPD), did not only alter E1B-55K PTM by SUMO itself, but additionally its ability to induce SUMO modification of p53 ( Figure 4Ca , lanes 6 and 7).
To validate the functional connection of both E1B-55K PTMs apart from p53 regulation (Figures 4A-C), we tested the ability of E1B-55K to decrease endogenous levels of the chromatinremodeling factor Daxx via a Cul5-dependent proteasomal mechanism, which has been shown to directly correlate with the SUMO modification of E1B-55K. 38, 49 As expected, all three proteins E1B-55K-wt/-NES/-3XPD ( Figure 4D , lanes 2, 4 and 6) induced reduction of endogenous Daxx, whereas E1B-55K-SCM/-3XPA failed to do so ( Figure 4D , lanes 3 and 5). Intriguingly, proteasomal degradation of p53 and Mre11 by the viral Cul5/Rbx1/ElonginB/C E3-ubiquitin ligase complex 50 occured independently of E1B-55K PTMs ( Figure 4E ), thus indicating substrate-specific roles for PTMs in E1B-55K-dependent degradation processes.
Finally, we tested the correlation of these mutations with the oncogenic potential of E1B-55K in primary baby rat kidney (pBRK) cells ( Figure 4F ). As expected, elimination of E1B-55K PTMs either by mutating the CPR ( Figure 4F , bar 6) or the SCM ( Figure 4F , bar 4) reduced focus-forming activity, whereas E1B-55K-wt ( Figure 4F , bar 3) induced efficient transformation of pBRK cells in combination with HAdV5 E1A. Moreover, both E1B-55K-NES and E1B-55-3XPD exhibited a comparable focus-forming activity ( Figure 4F , bars 5/7) than E1B-55K-wt ( Figure 4F , bar 3).
In total, these results provided strong evidence for a direct functional link between E1B-55K transformation potential and its PTMs ( Figure 4F ), in particular for the ability of the adenoviral protein to modulate p53 tumor suppressor functions ( Figures 4A-C) and the proteasome-mediated decrease of the chromatinremodeling factor Daxx ( Figure 4D ).
Interaction of Ubc9 and E1B-55K is independent of the PTMs SUMO modification involves a well-defined enzymatic cascade (Figure 1a) , which is frequently deregulated and/or utilized by pathogens. 19, 20 As E1B-55K itself is a target of the cellular SUMOylation machinery (Figures 2 and 3) 22,23 and at least partly depends on PTMs for certain functions (Figure 4) , 22, 23, [35] [36] [37] [38] we hypothesized that E1B-55K itself may be able to modulate enzymes involved in SUMO attachment.
To address this hypothesis, we investigated whether E1B-55K interacts with the E2 enzyme Ubc9 as many target proteins are assumed to either interact with Ubc9 and/or SUMO itself. Intriguingly, all tested adenoviral E1B-55K proteins interacted to different degrees with Ubc9 ( Figure 5 ). E1B-55K-NES and E1B-55K-3XPD showed a slightly higher affinity for Ubc9 compared with the less SUMOylated E1B-55K species both for exogenous ( Figure 5Aa ) and/or endogenous Ubc9 (Figure 5Ba ). In total, these data indicated that Ubc9 interacts with the viral protein, allowing direct access and, possibly, also modulation of the host cell SUMOylation machinery. However, based on the lack of a strict correlation between E1B-55K PTMs and the affinity for Ubc9, we concluded that this interaction is mostly independent of E1B-55K SUMOylation and/or phosphorylation.
E1B-55K PTMs regulate subnuclear localization during virus infection The HAdV5 E1B-55K protein is a multifunctional regulator, which mediates essential functions during the early and late phases of virus infection involving selective degradation of cellular substrates and preferential late viral mRNA export. 17, 51, 52 These 
during infection, which is dependent on the PTMs of the viral protein. 24 To determine the functional consequences of E1B-55K PTMs for productive viral infection, we analyzed the viruses H5pg4100 (wild type), H5pm4149 (E1B null), H5pm4102 (E1B-K104R), H5pm4101 (E1B-NES) and newly established mutants H5pm4174 (E1B-3XPA), H5pm4227 (E1B-3XPD). To confirm the correlation of both E1B-55K PTMs shown above, SUMO modification of the viral protein and interaction with Ubc9 was analyzed during infection ( Figure 6A ). As expected, both viruses expressing E1B-55K-NES or E1B-55K-3XPD (Figure 6Aa, lanes 5 and 7) , showed higher levels of SUMOmodified E1B-55K, whereas no equivalent species was evident for E1B-55K-SCM or E1B-55K-3XPA (Figure 6Aa, lanes 4 and 6) . Consistent with previous results (Figure 5 ), all E1B-55K mutants coprecipitated with the E2 enzyme Ubc9 during infection (Figure 6Ab) , except in the case of the E1B-55K null virus (Figure 6Ab, lane 3) .
Localization of E1B-55K during infection is dependent on multiple factors, including the presence of other viral proteins and PTMs. [22] [23] [24] 27, 28, 53, 54 Importantly, certain functions of E1B-55K have been suggested to depend on its potential to transiently localize to E2A-positive viral replication centers. 51, [55] [56] [57] [58] [59] As SUMO modification has been implicated in subnuclear targeting, we analyzed steady-state localization of E1B-55K to validate the regulative connection of both E1B-55K PTMs during infection ( Figure 6b ). As described previously, E1B-55K-wt showed a complex intracellular distribution pattern, ranging from small accumulations to a diffuse/slightly granular staining in the nucleus (Figure 6Ba) , 53 whereas efficient infection was indicated by formation of several, well-developed E2A-positive viral replication centers (Figure 6Bb ). However, enhanced SUMOylation of E1B-55K by mutating the NES induced a relocalization to brightly stained nuclear accumulations (Figure 6Bj ), clearly colocalizing with the centers of viral replication (Figure 6Bl ). 24 Furthermore, functional inactivation of E1B-55K SCM abolished the formation of nuclear aggregates (Figure 6Bg ) and colocalization with E2A-positive replication centers (Figure 6Bi) . Intriguingly, both E1B-55K proteins, harboring mutations within the CPR ( Figure 6 , H5pm4174 (E1B-55K-3XPA, Bm-Bo), H5pm4227 (E1B-55K-3XPD, Bp-Br)), matched the predicted possibility of a functional relationship between the E1B-55K PTMs. E1B-55K-3XPD showed higher levels of SUMO modification compared with E1B-55K-3XPA (Figure 6Aa , lanes 7 and 6), leading to an enhanced accumulation of the viral protein in the replication centers (Figure 6Br ), whereas the E1B-55K-3XPA mutant was both defective in SUMOylation (Figure 6Aa , lane 6) and subnuclear targeting (Figure 6Bo ). These results showed that the complicated interplay of a viral protein with the host cell PTM system alters subnuclear localization and, presumably, viral protein function during infection.
Future detailed studies are being planned to characterize the differential contributions of E1B-55K PTMs to basic protein functions, concerning selective degradation of cellular target proteins, viral mRNA transport and efficient virus replication.
DISCUSSION
The last 15 years of research have generated a tremendous amount of data concerning PTM by SUMO proteins and highlighted its importance in basic cell metabolism. Although it is not surprising that intracellular pathogens take advantage of this regulation system, little is known about the molecular mechanisms utilized by viruses. [19] [20] [21] In the context of HAdV5 infection, two proteins of the E1 region (E1A, E1B-55K) have been linked in some detail to the SUMOylation machinery. 22, 23, 60 E1B-55K is a multifunctional regulator that mediates a large variety of different molecular activities during early/late phases of infection, as well as in transformation of primary mammalian cells. 14, 52 In both contexts, modulation of the tumor suppressor p53 has been suggested to represent the predominant mechanism by which E1B-55K facilitates deregulation of cell cycle control and apoptosis, 13,14 although more efficient mechanisms might be present during viral infection. 36, 61 PTM of E1B-55K is essential for the modulation of p53; however, our present data on the functional connection between E1B-55K PTMs provide the first evidence for a unifying framework ( Figures  3 and 4) , explaining the so far unrelated data of a number of laboratories. [22] [23] [24] 27, 28, 36 Intriguingly, PTM of E1B-55K might also be a key determinant in selective degradation of the chromatinremodeling factor Daxx. Usually, E1B-55K forms a Skp1/Cullin/ F-box (SCF)-like E3-ubiquitin ligase complex in combination with the adenoviral E4orf6 protein, inducing proteasomal degradation of target proteins such as p53, 50 Mre11, 62 DNA-ligase IV 63 and integrin a3; 64 however, degradation of Daxx has been shown to occur independently of E4orf6 38 and dependent on E1B-55K PTMs ( Figure 4D ), whereas degradation of p53 and Mre11 is independent of E1B-55K SUMOylation and/or phosphorylation in the presence of E4orf6 ( Figure 4E ). Unfortunately, very little data is available comparing the detailed kinetics of substrate degradation/inactivation during productive viral infection. This would be of particular interest, because it has been shown that E1B-55K SUMO modification is gradually lost upon expression of E4orf6, 54 which might accordingly result in alterations of the degradation capabilities of E1B-55K and/or the E1B-55K/E4orf6 complex. Although clearly speculative at this point, it remains subject for further studies to evaluate whether E1B-55K PTM-dependent subnuclear targeting to PML-nuclear bodies, structures that have been suggested to have a role in nuclear protein degradation, 65, 66 has a role in Daxx degradation, whereas degradation of p53 and Mre11 mainly occurs in cytoplasmic aggresomes. 67 In summary, we have shown that mutational inactivation of either the SCM or the CPR interferes with the ability of E1B-55K to modulate the tumor suppressor protein p53 and chromatinremodeling factor Daxx, whereas the opposite phenotype is Figure 3 . E1B-55K phosphorylation effects subsequent SUMO modification. (A-C) H1299 cells were transfected with vector/pE1B-55K-wt/-SCM/-NES/-3XPA/-3XPD and vector/pHA-SUMO-1/-2/-3, harvested after 48 h and total cell extracts were prepared. Immunoprecipitation of E1B-55K was performed using mAb 2A6 (a-E1B-55K) and resolved on 10% SDS-PAGE. Precipitated proteins were detected using either mAb 2A6 (a-E1B-55K) (A) or mAb 3F10 (a-HA) (B), whereas input levels (C) were detected using mAb 2A6 (a-E1B-55K) and mAb AC-15 (a-b-actin). (D) H1299 cells were transfected with vector/pE1B-55K-wt/-SCM/-NES/-3XPA/-3XPD, harvested after 48 h and total cell extracts were prepared. IP of E1B-55K was performed using mAb 2A6 (a-E1B-55K) and resolved on 10% SDS-PAGE. Precipitated SUMO-conjugated proteins (a) and input levels (b) were detected by using mAb 8A2 (a-SUMO-2/3), mAb 2A6 (a-E1B-55K) and mAb AC-15 (a-b-actin). (E-G) H1299 cells were transfected with vector/pE1B-55K-wt/-SCM/-NES, alternatively treated with 5 mM DMAT or DMSO directly after transfection, harvested after 24 h and total cell extracts were prepared. Immunoprecipitation of E1B-55K or pST was performed using mAb 2A6 (a-E1B-55K; D) or mAb a-pST (E) and resolved on 10% SDS-PAGE. Precipitated proteins were detected using mAb 2A6 (a-E1B-55K; E, F), whereas input levels (G) were detected using mAb 2A6 (a-E1B-55K) and mAb AC-15 (a-b-actin). (H) H1299 cells were transfected with vector/pE1B-55K-wt/-SCM/-NES/-3XPA/-3XPD/-NES-3XPD and pHA-SUMO-1/2/3-GG, harvested after 48 h and total cell extracts were prepared. IP of E1B-55K was performed using mAb 2A6 (a-E1B-55K) and resolved on 10% SDS-PAGE. Directly precipitated proteins (a) and input levels (b) were detected by using mAb 2A6 (a-E1B-55K) and mAb AC-15 (a-b-actin). Molecular weight in kDa is indicated on the left, while proteins are labeled on the right. Figure 4 . E1B-55K oncogenic properties are dependent on the cross-talk of both PTMs. (A/B) H1299 cells were transfected with 1 mg pRenilla-Luc, 0.3 mg artifical (A)/endogenous (B) p53-dependent reporter construct (pRE-Luc/pcyclinG-Luc), 0.02 mg p53SN3 and alternatively vector/ pE1B-55K-wt/-SCM/-NES/-3XPA/-3XPD as indicated. Forty-eight hours after transfection total cell extracts were prepared and luciferase activity was determined. The mean and s.d.'s are presented for three independent experiments. Luciferase samples were immunoblotted and probed with mAb 2A6 (a-E1B-55K) and mAb AC-15 (a-b-actin). Asterisks reflect the different amounts of transfected pE1B-55K-wt (0.5 mg*; 1.0 mg**). (C) H1299 cells were transfected with vector/pE1B-55K-wt/-SCM/-NES/-3XPA/-3XPD and p53SN3, harvested after 36 h and total cell extracts were prepared. Immunoprecipitation of p53 was performed using mAB DO-I (a-p53) and resolved on 10% SDS-PAGE. Precipitated proteins (a) and input levels (b) were detected using mAb 2A6 (a-E1B-55K), mAb DO-I (a-p53) and mAb AC-15 (a-b-actin). (D) H1299 cells were transfected with vector/pE1B-55K-wt/-SCM/-NES/-3XPA/-3XPD, harvested after 72 h, total cell extracts were prepared and resolved on 10% SDS-PAGE. Input levels were detected by using mAb 2A6 (a-E1B-55K), pAb a-Daxx and mAb AC-15 (a-b-actin). (E) H1299 cells were transfected with different combinations of 0.25 mg p53SN53, 0.75 mg pE4orf6 and pE1B-55K-wt/-SCM/-NES/-3XPA/-3XPD, harvested after 24 h, total cell extracts were prepared and resolved on 10% SDS-PAGE. Input levels were detected by using pAb a-Mre11, mAb DO-I (a-p53), mAb 2A6 (a-E1B-55K), pAb 1807 (a-E4orf6) and mAb AC-15 (a-b-actin). Molecular weight in kDa is indicated on the left, while proteins are labeled on the right. (F) pBRK cells were transfected with pXC15, harboring the alternative mutations within the E1B ORF as indicated, and grown for 21 days. Finally, focus formation was visualized by crystal violet staining, quantified and normalized to pXC15-E1B-wt. Representative results of three independent experiments are shown.
induced by mutations that enhance the SUMOylation of E1B-55K. These findings are consistent and integrate both p53-dependent and -independent mechanisms in their importance for the ability of E1B-55K to induce malignant transformation of primary mammalian cells ( Figure 4F) . 37, 38, 47, 68 The potential target for E1B-55K modification by all three SUMO paralogues is an interesting observation, but the in vivo relevance and functional consequences remain to be demonstrated. Although, Penella et al. 36 showed recently that p53 is only modified by SUMO-1 during viral infection, these studies do not exclude modification by other SUMO paralogues under specific conditions or of additional, so far unknown, cellular proteins. As attachment of alternative SUMO paralogues can drastically modify both the structure and functions of target proteins, our ongoing studies may soon reveal whether this applies also to modification of E1B-55K by different SUMO paralogues.
Interestingly, newest data convincingly show that C-terminal phosphorylation of E1B-55K is at least in part regulated by CK2, 29, 69 as in particular the catalytic subunit CK2a is redistributed into ring-like E1B-55K positive nuclear areas during productive virus infection. Following the assumption that phosphorylation of E1B-55K preferentially occurs at these nuclear accumulations, 29 our results of sequential SUMOylation would explain the previously described phenomenon of SUMO-dependent nuclear matrix association of E1B-55K during the very early phase of infection, 54, 70 whereas delayed expression of E4orf6 initiates a gradual loss of E1B-55K PTM and nuclear matrix association. 54 In addition, the observation that E1B-55K itself interacts with the SUMO E2 enzyme Ubc9 offers a new opportunity to analyze the interplay of the viral protein with the host cell SUMO modification system. Interestingly, previous reports concerning transcription factors MEF2 and HSF1 showed that phosphorylation facilitates SUMO modification by Ubc9, although the interaction of both partners is independent of phosphorylation. 71 This observation is somehow reminiscent of the inability of E1B-55K-SCM or E1B-55K-3XPA to be SUMOylated and/or to induce SUMO modification of the tumor suppressor p53, despite their continuing ability to bind the E2 enzyme Ubc9. We currently favor the model that phosphorylation of E1B-55K might be necessary to stimulate the enzymatic activity of Ubc9, allowing SUMO transfer onto the viral protein itself and/or p53. However, it additionally remains possible that phosphorylation of E1B-55K assists in non-covalent interaction with SUMO and/or SUMO-Ubc9 thus facilitating covalent modification of the viral protein, a mechanism similar to the one described for Daxx. 72, 73 Ongoing studies are dedicated to establish a suitable in vitro system to obtain more resilient results on the functional interplay between E1B-55K and components of the cellular SUMO modification system.
The molecular 3-dimensional protein structure of Ubc9 is known in detail 74 and led to the characterization of determinants implicated in interactions with target proteins. Based on more recent descriptions of Ubc9 interaction partners, 75 we assume that E1B-55K harbors a specific kind of SCM motif, aptly termed negatively charged amino-acid dependent SUMOylation motif. This motif is characterized by the consensus sequence c-K-x-E-x (2-5) -D/E-x (2) -D/E and is present on all E1B-55K proteins of species C adenoviruses (Figure 1b, Figure 7 ), thus enabling simultaneous interaction with the catalytic groove and the nearby basic patch of Ubc9. Additionally, E1B-55K contains a LK dipeptide directly N-terminal of the SCM (Figures 1b and 7B) , which may contribute to its binding to the E2 enzyme in a fashion similar to that observed with the HPV E1 protein. 76 Figure 7 shows that putatively phosphorylatable residues are present at the C-terminus in all species, thus strongly suggesting that phosphorylation is of general importance for E1B-55K function as these sites have been maintained throughout adenovirus evolution. In the case of SUMOylation, the consensus c-K-x-E motif is also highly conserved among HAdVs, with the exception of species A, F and G. Thus E1B-55K SUMOylation might not occur with all human adenoviruses (HAdV) species. Further studies need to be carried out to determine if SUMOylation of E1B-55K occurs in species A, F α-E2A Figure 6 . E1B-55K's PTMs regulate subnuclear localization during productive infection. (A) H1299 cells were infected with mock, E1B-55K-wt (H5pg4100), E1B-55K-minus (H5pm4149), E1B-55K-SCM (H5pm4102), E1B-55K-NES (H5pm4101), E1B-55K-3XPA (H5pm4174) and E1B-55K-3XPD (H5pm4227) virus (moi 10), harvested after 36 h p.i. and total cell extracts were prepared. Immunoprecipitation of E1B-55K or Ubc9 was performed using mAb 2A6 (a-E1B-55K) or mAb a-Ubc9 and resolved on 10% SDS-PAGE. Coprecipitated proteins (Aa/Ab) and input levels (A(c)) were detected by using mAb 2A6 (a-E1B-55K), mAb B6-8 (a-E2A), mAb a-Ubc9 and mAb AC-15 (a-b-actin). Molecular weight in kDa is indicated on the left, while proteins are labeled on the right. (B) H1299 cells were infected with wt (H5pg4100) and mutant viruses (H5pm4149, H5pm4102, H5pm4101, H5pm4174, H5pm4227) (moi 10) and fixed with methanol after 48 h p.i. Samples were double-labeled in situ with mAb 4E8 (a-E1B-55K) and mAb B6-8 (a-E2A). Primary antibodies were detected with Cy3-and FITC-conjugated secondary antibodies, respectively. Representative a-E1B-55K (red; subpanels a, d, g, j, m, p) and a-E2A (green; subpanels b, e, h, k, n, q) staining patterns are shown. The overlays of the single images (merge) are shown in subpanels c, f, i, l, o and r, including visualization of the nuclei by 4' ,6-diamidino-2-phenylindole staining. To illustrate the subnuclear localization of E1B-55K and E2A in sufficient detail, representative single cell images are provided, whereas the frequency of observed subcellular localization patterns are documented as percentages of at least 50 analyzed cells.
and G viruses, which are phylogenetically grouped separately and exhibit different tissue specificity during infection in vivo ( Figure 7B ). This could be a characteristic that has been gained or lost with the evolution of adenoviruses that replicate efficiently in different tissues. Taken together, our data provide the first evidence for a functional relationship between two so far unlinked PTMs of the viral E1B-55K oncoprotein, enabling modulation of various host cell factors (for example, p53, Daxx, Ubc9). Moreover, the identified interaction of E1B-55K with Ubc9 offers a new insight into how HAdVs in general may actively interfere/modulate the host cell SUMOylation machinery. Cell lines and culture conditions   H1299,  77 HEK293 78 and pBRK cells 79 were grown in Dulbecco's modified Eagle's medium with 10% FCS (fetal calf serum), 100 U penicillin and 100 mg streptomycin per ml in 5% CO 2 atmosphere at 37 1C.
MATERIALS AND METHODS

Plasmids, transient transfections and reporter gene assays
HAdV5 E1B-55K-wt, the E1B mutant proteins E1B-55K-NES (L83/87/91A), E1B-55K-SCM (K104R), 23 E1B-55K-3XPA (S490/1T495A) 27, 28 and E1B-55K-3XPD (S490/1T495D), 31 E4orf6, 80 p53, 81 N-terminally HA-tagged Ubc9 82 and SUMO-1/2/3 lacking amino acid 98-101/94-95/93-103 from the C-terminus (provided by R. Hay) were expressed from pcDNA3. Subconfluent cells were transfected using 25 kDa PEI (Polysciences Europe GmbH, Eppelheim, Germany). 37 For dual luciferase assays, H1299 cells were transfected with indicated amounts of reporter and effector plasmids (see Figure 4 ) and 1.0 mg of pRL-TK (Promega, Madison, WI, USA). The p53-dependent reporter constructs (pRE-Luc, pcyclinG-Luc) for expression of Firefly luciferase have been described. 23, 83 Total cell extracts were prepared 36 h after transfection and Firefly activity was assayed in a luminometer (Lumat LB9510, Berthold Technologies GmbH & Co.KG, Bad Wildbad, Germany). All samples were normalized for transfection efficiency by measuring Renilla activity.
Transformation assays
To test the oncogenic potential of E1B-55K plus E1A, freshly prepared pBRK cells were generated from 3-5 days old CD rats (Charles River, Wilmington, MA, USA). 79 Subsequently, 3 Â 10 6 pBRK cells were transfected with pXC15 plasmid 84 or versions respective mutations in the E1B open reading frame (ORF). Cells were expanded onto 150-mm culture plates after 48 h, cultivated for 2-3 weeks changing the medium every 3-4 days and multilayered cell accumulations (foci) were visualized by crystal violet staining. rabbit pAb (Abcam, Cambridge, UK), a-mre11 rabbit pAb (Novus Biologicals Ltd., Cambridge, UK), a-b-actin mouse mAb AC-15 (SigmaAldrich) and a-HA rat mAb 3F10 (provided by E Kremmer). All protein extracts were prepared in RIPA buffer (50 mM Tris-HCl/pH 8.0, 150 mM NaCl, 5 mM EDTA, 1 mM dithiothreitol (DTT), 0.1% sodium dodecyl sulfate, 1% NP-40, 0.1% Triton X-100, 0.5% sodiumdeoxycholate) containing 1% phenylmethylsulfonyl fluoride (PMSF), 0.1% aprotinin, 1 mg/ml leupeptin, 1 mg/ml pepstatin, 1 mM DTT, 25 mM iodacetamide and 25 mM N-ethylmaleimide. For immunoprecipitation (IP) proteinA-Sepharose/ proteinG-agarose was coupled with primary Ab for 1 h at 4 1C, added to precleared extracts and rotated for 2 h at 4 1C. Proteins bound to beads were precipitated by centrifugation, washed three times and boiled for 3 min at 95 1C in 2xLaemmli buffer. For immunoblotting of protein input levels/IP solutions equal amounts were separated by SDS-polyacrylamide gel electrophoresis, transferred to nitrocellulose (Schleicher & Schü ll/Whatman) and incubated as described. 87 Bands were visualized by enhanced chemoluminescence (ECL) (Pierce, Thermo Scientific, Rockford, IL, USA) on X-ray films (CEA RP X-ray film). Autoradiograms were scanned, cropped and prepared using Adobe PhotoshopCS4/IllustratorCS4 (Adobe Systems GmbH, Mö nchen, Germany).
Indirect immunofluorescence
For IF, cells were grown on glass coverslips as described. 22 Cells were fixed in ice-cold methanol at À 20 1C for 15 min for regular or alternatively at room temperature for 15 min with 4% paraformaldehyde for confocal microscopy and permeabilized in phosphate-buffered saline (0.5% Triton X-100) for 30 min. After 1 h blocking in Tris-buffered saline-BSA/glycine (TBS-BG) buffer, coverslips were treated for 1 h with primary Abs, washed three times in phosphate-buffered saline (0.1% Tween20) followed by incubation with the corresponding FITC-/Cy3-or Alex549/Alesxa488-conjugated secondary Abs (Dianova GmbH, Hamburg, Germany). Coverslips were washed three times in phosphate-buffered saline (0.1% Tween20), mounted in Glow medium (Energene, MoBiTec, Gö ttingen, Germany) and digital images were acquired on a DMRB or LSM3 confocal microscope. Images were cropped using Adobe PhotoshopCS4/ IllustratorCS4.
